- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02149030
Effectiveness of Cervical Screening in HPV Vaccinated Women (HPV-004)
Effectiveness of Cervical Screening in HPV Vaccinated Women - A Randomized Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Altogether 16.500 1992-1995 born women vaccinated with the bi-valent human papillomavirus type 16 and 18 (HPV16/18) vaccine as adolescents either at the age of 12 to 15 or at the age of 18 will be invited to an effectiveness trial at the age of 22 years, and randomized into Arms A1 and A2, and A3, respectively.
Cervical samples and cervico-vaginal self-samples rinsed in first-void urine will be analysed for HPV and C. trachomatis DNA with MGP primer system followed by MALDITOF mass spectrometry on the SEQUENOM platform (HPV) and the Abbott™ PCR (Chlamydia trachomatis), respectively.
With assumed >50% participation the trial has 80% power to show non-inferiority of the infrequent vs. the frequent screening information.
A one-way (participant) blinded interim analysis among the 1992-born study participants in A1 and A3 arms, who have attended the 2nd study visit at the age of 25 years, will be performed in 2017 for assuring no statistically significant differences in the cervical intraepithelial neoplasia grade 2/3 (CIN2/CIN3) incidences of the two arms.
At the study end testing the null hypotheses of no difference in the incidence of the CIN2/3 end-points between the A1 and A2 intervention arms will be done using the Mantel-Haenszel one degree of freedom chi-square statistics.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Helsinki, Finland
- HUS
-
Hyvinkää, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Hämeenlinna, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Iisalmi, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Joensuu, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Jyväskylä, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Jämsä, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Kajaani, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Kemi, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Kokkola, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Kotka, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Kouvola, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Kuopio, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Lahti, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Lappeenranta, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Lohja, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Mikkeli, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Oulu, Finland
- THL
-
Pori, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Porvoo, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Rauma, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Rovaniemi, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Salo, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Savonlinna, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Seinäjoki, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Tampere, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Turku, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Vaasa, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Vammala, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Varkaus, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
Äänekoski, Finland
- Nuorisotutkimusasema: Tampereen yliopisto
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HPV 16/18 vaccinated. Born 1992-1995.
Exclusion Criteria:
- Immunocompromising disease. HPV 6/11/16/18 vaccination.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A1
A1) Cytological screening in A1 and A3.
Frequent information of screening results for cytology and/or HPV DNA at the ages of 22 (cytology only), 25 and 30.
|
Cytological screening.
|
No Intervention: A2
A2) infrequent information of screening results, only at the age 30 years.
|
|
Other: A3
A3) Cytological screening in A1 and A3.
With at least 1000 participants is enrolled for interim safety analysis when the 1992 birth cohort is 25 years of age and cytology results are being revealed.
|
Cytological screening.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Occurrence of intraepithelial neoplasia grade 2/3 (CIN2/3).
Time Frame: 2017(interim), 2026 (final analysis). Participants will be followed for the duration of the study until 2026, an expected average of 9 years.
|
1a) No marked difference in the incidence of CIN2/3 between arms A1 (participants frequently informed of the cytological results) and A3 (participants not informed of the cytological findings at the age of 22) (interim analysis). 1b) No difference in the incidence of CIN2/3 between arms A1 (participants frequently informed of the cytological results) and A2 (participants infrequently informed of the cytological results). The participants will be followed for 9 years starting from the year they turn 22. For 1992 born the follow-up will start in 2014 and end in 2023. For 1995 born the follow-up will start in 2017 and end in 2026. The interim analysis will include only 1992 cohort. The final analysis will include all cohorts (1992, 1993, 1994, 1995). |
2017(interim), 2026 (final analysis). Participants will be followed for the duration of the study until 2026, an expected average of 9 years.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Matti Lehtinen, MD, PhD, Tampere University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HPV-004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Intraepithelial Neoplasia Grade 2/3
-
National Cancer Institute (NCI)TerminatedCervical Cancer | Cervical Intraepithelial Neoplasia Grade 2 | Cervical Intraepithelial Neoplasia Grade 3United States
-
BioLeaders CorporationUnknownCervical Intraepithelial Neoplasia Grade 2/3Korea, Republic of
-
GY Highland Biotech LLCUnknownCervical Intraepithelial Neoplasia Grade 2/3United States
-
Asieris MediTech (Hong Kong) Co., Ltd.Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3China
-
Krankenhaus Barmherzige Schwestern LinzMedical University of ViennaCompletedCervical Intraepithelial Neoplasia Grade 1 | Cervical Intraepithelial Neoplasia Grade 2Austria
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Carcinoma | Cervical Intraepithelial Neoplasia Grade 2/3 | Stage 0 Cervical CancerUnited States
-
Tampere University HospitalKarolinska Institutet; Tampere University; European UnionEnrolling by invitationCervical Intraepithelial Neoplasia Grade 2/3 | Adenocarcinoma in SituFinland
-
National Cancer Institute (NCI)Active, not recruitingCervical Intraepithelial Neoplasia Grade 2/3 | High Grade Cervical Intraepithelial Neoplasia | Cervical Squamous Cell Carcinoma In Situ | Cervical Squamous Intraepithelial Neoplasia 2United States
-
ViMREX GmbHFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus...Active, not recruitingVulvar Intraepithelial Neoplasia Grade 2 | Vulvar Intraepithelial Neoplasia Grade 3Germany
-
Marc ArbynUniversity Hospital, Ghent; Universitair Ziekenhuis Brussel; University Hospital... and other collaboratorsActive, not recruitingCervical Intraepithelial Neoplasia Grade 2/3Belgium
Clinical Trials on Cytological screening in A1 and A3
-
Penn State UniversityWithdrawnNeuroblastoma | Osteogenic Sarcoma | Rhabdomyosarcoma
-
Alexza Pharmaceuticals, Inc.CompletedParkinson's DiseaseNetherlands
-
a2 Milk Company Ltd.Completed
-
Africa Mental Health FoundationUniversity of British Columbia; Grand Challenges Canada; Nextgenu.org; CliniX Healthcare... and other collaboratorsCompletedSubstance-Related Disorders | Alcohol-Related Disorders | Social StigmaKenya
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)WithdrawnYoung Adult-Mediated Intervention to Increase Colorectal Cancer Screening
-
Sohag UniversityRecruitingUrinary Stone | Hip Abnormalities | Femur; Angulation | Lower Limb Arterial EmbolusEgypt
-
Hospital Universitario Infanta LeonorFundacion SEIMC-GESIDA; Instituto de Salud Carlos IIICompletedHepatitis C | HIV | Harm Reduction | Drug Users
-
Children's Cancer Group, ChinaQilu Hospital of Shandong University; Shanghai Children's Medical Center; West... and other collaboratorsRecruitingPediatric Anaplastic Large Cell LymphomaChina
-
University Health Network, TorontoNot yet recruiting
-
Yeşim KAYAPARecruiting